

PRESS RELEASE

Yamanouchi Concludes Co-promotion Agreement with US Boehringer Ingelheim for FLOMAX® for the Treatment of Functional Symptoms of Benign Prostatic Hyperplasia

Tokyo - 16 August 2004 - Yamanouchi Pharmaceutical Co., Ltd. ("Yamanouchi"; President and CEO: Toichi Takenaka) announced that it has concluded an agreement for co-promoting FLOMAX® (generic name: tamsulosin HCl; brand name in Japan: Harnal®) in the US with Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiary of Boehringer Ingelheim based in Ingelheim, Germany. Yamanouchi Pharma America (YPA), Yamanouchi's US subsidiary, will start co-promotion of the product with Boehringer Ingelheim Pharmaceuticals, Inc. in October 2004.

Discovered by Yamanouchi, tamsulosin HCl, an α_1 -adrenoceptor antagonist, is the first alpha blocker specifically developed for BPH symptoms treatment. It was first launched in Japan in 1993 and is now marketed in 64 countries. Boehringer Ingelheim Pharmaceuticals, Inc., licensed by Yamanouchi, has marketed FLOMAX® capsules in the US since 1997. Tamsulosin's worldwide sales¹ exceeded ¥190 billion last year. Based on its established efficacy and safety profile, it has steadily penetrated the world market, and it has become the most widely prescribed drug for BPH, in not only the US, but also the world market.

At present, Yamanouchi is constructing its own marketing system in the US with a special focus in the urology field. YPA already has its own medical representatives (MRs) for promotion who will be targeting urologists. The Company plans to hire additional MRs for promotion targeting primary care physicians (PCP) and conduct co-promotion in both the specialist and PCP markets in order to maximize the value of FLOMAX®.

The treatment for urinary frequency and urinary incontinence Vesicare®, whose NDA is under review by the Food and Drugs Administration (FDA), is expected to be launched by Yamanouchi at the end of 2004 as the first product the Company will independently market in the US. The new co-promotion agreement expands the company's product lineup in the US market for urological products. Yamanouchi is committed to further strengthening its business base in the US market by initiating marketing activities in not only in the specialist market but also the PCP market.

¹ Sales in the market including the sales by licensees

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Pharmaceutical Co., Ltd., established in 1923 and headquartered in Tokyo, Japan, is a leading pharmaceutical company in Japan. Yamanouchi is expanding its business base to Europe, the United States and Asia and employs about 9,000 people worldwide (FY ended March 2004). As a research-based developer, manufacturer and marketer, Yamanouchi has introduced several world-class drugs to the international market, including the H2 antagonist, famotidine; the calcium antagonist, nifedipine; and tamsulosin, a treatment for functional symptoms of benign prostatic hyperplasia.

More information concerning Yamanouchi can be found on its Web site at

<http://www.yamanouchi.com>

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2003, Boehringer Ingelheim posted net sales of US \$8.37 billion (7.4 billion euro) while spending more than one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information please visit www.boehringer-ingelheim.com.

Boehringer Ingelheim and Yamanouchi also cooperate in Japan to co-promote MICARDIS® monotherapy (generic name telmisartan), an angiotensin II receptor antagonist discovered and developed by Boehringer Ingelheim for the treatment of hypertension.